Trandolapril
| Clinical data | |
|---|---|
| Trade names | Mavik, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a697010 |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | Trandolapril 80% (independent of concentration) Trandolaprilat 65 to 94% (concentration-dependent) |
| Metabolism | Liver |
| Elimination half-life | 6 hours (trandolapril) 10 hours (trandolaprilat) |
| Excretion | Fecal and Kidney |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.108.532 |
| Chemical and physical data | |
| Formula | C24H34N2O5 |
| Molar mass | 430.545 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 119 to 123 °C (246 to 253 °F) |
SMILES
| |
InChI
| |
| (verify) | |
Trandolapril is an ACE inhibitor used to treat high blood pressure. It may also be used to treat other conditions. It is similar in structure to another ramipril but has a cyclohexane group. It is a prodrug that must be metabolized into its active form. It has a longer half-life when compared to other agents in this class.
It was patented in 1981 and approved for medical use in 1993.[1] It is marketed by Abbott Laboratories under the brand name Mavik.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 469. ISBN 9783527607495.